Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present)

Bibliography

• Lundström L, Spooren W, Gatti McArthur S. Excitatory amino acids and their antagonists. In: Stolerman I, editor. Encyclopedia of psychopharmacology. Springer; Berlin Heidelberg: 2010. p. 508-16; and 2014 second edition in preparation
   Google Scholar
• Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010;50:295-322
   PubMed Web of Science ®Google Scholar
• Fell MJ, McKinzie DL, Monn JA, et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012;62(3):1473-83
   PubMed Web of Science ®Google Scholar
• Trabanco AA, Cid JM. mGluR2 positive allosteric modulators: a patent review (2009 - present). Expert OpinTher Pat 2013;23(5):629-47
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014;20(9):947-56
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Berry-Kravis E, Hagerman R, et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 2014;23(1):125-34
   PubMed Web of Science ®Google Scholar
• Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res 2006;326(2):483-504
   PubMed Web of Science ®Google Scholar
• Yin S, Niswender CM. Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cell Signal 2014;26(10):2284-97
   PubMed Web of Science ®Google Scholar
• Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 2013;9(9):948-59
   PubMed Web of Science ®Google Scholar
• Brunner J, Ster J, Van-Weert S, et al. Selective silencing of individual dendritic branches by an mGlu2-activated potassium conductance in dentate gyrus granule cells. J Neurosci 2013;33(17):7285-98
   PubMed Web of Science ®Google Scholar
• Nicholls RE, Zhang XL, Bailey CP, et al. mGluR2 acts through inhibitory Galpha subunits to regulate transmission and long-term plasticity at hippocampal mossy fiber-CA3 synapses. Proc Natl Acad Sci USA 2006;103(16):6380-5
   PubMed Web of Science ®Google Scholar
• Lundstrom L, Bissantz C, Beck J, et al. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol 2011;164(2b):521-37
   PubMed Web of Science ®Google Scholar
• Upreti C, Zhang XL, Alford S, Stanton PK. Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release. Neuropharmacology 2013;66:31-9
   PubMed Web of Science ®Google Scholar
• Gu G, Lorrain DS, Wei H, et al. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Res 2008;1197:47-62
   PubMed Web of Science ®Google Scholar
• Iyer AM, van Scheppingen J, Milenkovic I, et al. Metabotropic glutamate receptor 5 in down’s syndrome hippocampus during development: increased expression in astrocytes. Curr Alzheimer Res 2014;11(7):694-705
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Wolswijk G, Bö L, et al. Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. J Neuroimmunol 2005;158(1-2):182-90
   PubMed Web of Science ®Google Scholar
• Lundström L, Kuhn B, Beck J, et al. Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist [3H]-HYDIA. ChemMedChem 2009;4(7):1086-94
   PubMed Web of Science ®Google Scholar
• Kratochwil NA, Gatti-McArthur S, Hoener MC, et al. G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. Curr Top Med Chem 2011;11(15):1902-24
   PubMed Web of Science ®Google Scholar
• Richards G, Messer J, Malherbe P, et al. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding. J Comp Neurol 2005;487(1):15-27
   PubMed Web of Science ®Google Scholar
• Wermuth CG, Mann A, Schoenfelder A, et al. (2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylatecyclase. J Med Chem 1996;39(4):814-16
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Marinozzi M, Natalini B, et al. Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2’-carboxy-3’-phenylcyclopropyl)glycine. Focus on (2S,1’S,2’S,3’R)-2-(2’-carboxy-3’-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist. J Med Chem 1996;39(11):2259-69
   PubMed Web of Science ®Google Scholar
• Ornstein PL, Bleisch TJ, Arnold MB, et al. 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. J Med Chem 1998;41(3):346-57
   PubMed Web of Science ®Google Scholar
• Ornstein PL, Bleisch TJ, Arnold MB, et al. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. J Med Chem 1998;41(3):358-78
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Adam G, Huguenin P, et al. Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA. ChemMedChem 2008;3(2):323-35
   PubMed Web of Science ®Google Scholar
• Nakazato A, Sakagami K, Yasuhara A, et al. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem 2004;47(18):4570-87
   PubMed Web of Science ®Google Scholar
• Koike H, Iijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011;61(8):1419-23
   PubMed Web of Science ®Google Scholar
• Ago Y, Yano K, Araki R, et al. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 2013;65:29-38
   PubMed Web of Science ®Google Scholar
• Karasawa J, Shimazaki T, Kawashima N, et al. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005;1042(1):92-8
   PubMed Web of Science ®Google Scholar
• Koike H, Fukumoto K, Iijima M, et al. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 2013;238:48-52
   PubMed Web of Science ®Google Scholar
• Feinberg I, Schoepp DD, Hsieh KC, et al. The metabotropic glutamate (mGlu)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGlu2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. J Pharmacol Exp Ther 2005;312(2):826-33
   PubMed Web of Science ®Google Scholar
• Ahnaou A, Ver Donck L, Drinkenburg WH. Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: evidence from sleep-wake EEG in rodents. Behav Brain Res 2014;270:56-67
   PubMed Web of Science ®Google Scholar
• Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004;46(4):457-67
   PubMed Web of Science ®Google Scholar
• Pałucha-Poniewiera A, Wierońska JM, Brański P, et al. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) 2010;212(4):523-35
   PubMed Web of Science ®Google Scholar
• Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 2004;501(1-3):121-5
   PubMed Web of Science ®Google Scholar
• Yoshimizu T, Shimazaki T, Ito A, et al. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006;186(4):587-93
   PubMed Web of Science ®Google Scholar
• Iijima M, Shimazaki T, Ito A, et al. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl) 2007;190(2):233-9
   PubMed Web of Science ®Google Scholar
• Stachowicz K, Wierońska J, Domin H, et al. Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent. Pharmacol Rep 2011;63(4):880-7
   PubMed Web of Science ®Google Scholar
• Yoshimizu T, Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004;315(2):493-6
   PubMed Web of Science ®Google Scholar
• Braincells, Inc. Method for increasing the oral bioavailability of a metabotropic glutamate 2/3 receptor antagonist. WO059111; 2014
   Google Scholar
• Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders. WO062680; 2013
   Google Scholar
• Nakamura M, Kawakita Y, Yasuhara A, et al. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of MGS0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist. Drug Metab Dispos 2006;34(3):369-74
   PubMed Web of Science ®Google Scholar
• Yasuhara A, Sakagami K, Yoshikawa R, et al. Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists. Bioorg Med Chem 2006;14(10):3405-20
   PubMed Web of Science ®Google Scholar
• Yasuhara A, Nakamura M, Sakagami K, et al. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 2006;14(12):4193-207
   PubMed Web of Science ®Google Scholar
• Kim SH, Steele JW, Lee SW, et al. Proneurogenic Group II mGluR antagonist improves learningand reduces anxiety in Alzheimer Abeta oligomer mouse. Mol Psychiatry 2014;19(11):1235-42
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01548703 [Last accessed 31 July 2014]
   Google Scholar
• Press release. Available from: http://www.prnewswire.com/news-releases/braincells-inc-announces-the-successful-completion-of-a-multiple-ascending-dose-study-of-bci-838-a-group-ii-mglur23-antagonist-and-the-companys-plans-for-a-proof-of-concept-study-in-patients-with-treatment-resistant-depress-182166091.html [Last accessed 31 July 2014]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/record/NCT01546051 [Last accessed 31 July 2014]
   Google Scholar
• Eli Lilly and Co. 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists. WO068041; 2012
   Google Scholar
• Eli Lilly and Company. 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists. WO068067; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. Benzodiazepine derivatives as metabotropic glutamate receptor antagonists. WO 29011; 2001
   Google Scholar
• F. Hoffmann-La Roche AG. Benzodiazepine derivatives as metabotropic glutamate receptor antagonists. WO 29012; 2001
   Google Scholar
• F. Hoffmann-La Roche AG. Dihydrobenzo[b][1,4]diazepin-2-ones as mGluR2 antagonists for treatment of neurological disorders. WO83652; 2002
   Google Scholar
• F. Hoffmann-La Roche AG. Dihydro-benzo[b][1,4]diazepin-2-one derivatives as metabotropic glutamate receptor 2 (mGluR2) antagonists. WO83665; 2002
   Google Scholar
• F. Hoffmann-La Roche AG. Dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders. WO066623; 2003
   Google Scholar
• Woltering TJ, Adam G, Wichmann J, et al. Synthesis and characterization of 8-ethynyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1. Bioorg Med Chem Lett 2007;17:6811-15
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Adam G, Wichmann J, et al. Synthesis and characterization of 8-ethynyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one derivatives: part 2. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett 2008;18:1091-5
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Wichmann J, Goetschi E, et al. Synthesis and characterization of 8-ethynyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one derivatives: part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett 2008;18:2725-9
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Wichmann J, Goetschi E, et al. Synthesis and characterization of 8-ethynyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one derivatives: part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett 2010;20:6969-74
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Wichmann J, Goetschi E, et al. 1,3-Dihydrobenzo[b][1,4]diazepin-2-one derivatives as potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Abstracts of the 7th International Meeting on Metabotropic Glutamate Receptors. Cur Neuropharmacol 2011;9(Suppl 1):67; abstract 184
   Google Scholar
• Goeldner C, Ballard T, Knoflach F, et al. Cognitive impairment in major depression and mGlu2 receptor as a therapeutic target. Neuropharmacology 2013;64:337-46
   PubMed Web of Science ®Google Scholar
• Biesmans I, Megens A, Bouwknecht JA, et al. In vitro and in vivo Characterization of two mGlu2/3 Negative Allosteric Modulators. Abstracts of the 7th International Meeting on Metabotropic Glutamate Receptors. Curr Neuropharmacol 2011;9(Suppl 1):5; abstract 15
   Google Scholar
• Van der Linden I, Peeters L, Biesmans I, et al. In vitro characterization of the binding of the mGlu2 receptor positive allosteric modulator [3H]JNJ-40068782 to native and recombinant mGlu2 receptors. Abstracts of the 7th International Meeting on Metabotropic Glutamate Receptors. Curr Neuropharmacol 2011;9(Suppl 1):63; abstract 175
   PubMedGoogle Scholar
• Ballard TM, Knoflach F, Woltering TJ, et al. Selective mGlu2/3 receptor NAM alleviate pharmacological or age-related cognitive impairment in rodents and monkeys. Abstracts of the 7th International Meeting on Metabotropic Glutamate Receptors. Curr Neuropharmacol 2011;9(Suppl 1):3; abstract 7
   Google Scholar
• F. Hoffmann-La Roche Ltd. Combination of mGluR2 antagonist and AChE inhibitor for treatment of acute and/or chronic neurological disorders. WO014002; 2005
   Google Scholar
• Campo B, Kalinichev M, Lambeng N, et al. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet 2011;25(4):152-66
   PubMed Web of Science ®Google Scholar
• Ahnaou A, Ver Donck L, Drinkenburg WH. Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: evidence from sleep-wake EEG in rodents. Behav Brain Res 2014;270:56-67
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche AG. Dihydrobenzo[b][1,4]diazepin-2-one biphenylsulfonamides as group II mGlu receptor antagonists. US0261957; 2008
   Google Scholar
• Hemstapat K, Da Costa H, Nong Y, et al. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol ExpTher 2007;322:254-64
   PubMed Web of Science ®Google Scholar
• BrainCells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof. WO033246; 2013
   Google Scholar
• F. Hoffmann-La Roche AG. Pyridine and pyrimidine derivatives as mGluR2 antagonists. WO110337; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. mGlu2/3 antagonists for the treatment of autistic disorders. WO064028; 2014
   Google Scholar
• F. Hoffmann-La Roche AG. Pyridine and pyrimidine derivatives as mGluR2 antagonists. WO119689; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrazolo and imidazo-pyrimidine derivatives. WO040171; 2005
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrazolo-pyrimidine derivatives. WO123738; 2005
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrazolo-pyrimidine derivatives as mGluR2 antagonists. WO084634; 2006
   Google Scholar
• F. Hoffmann-La Roche AG. Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists. WO099972; 2006
   Google Scholar
• F. Hoffmann-La Roche AG. Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists. WO039439; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Methods for the preparation of 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine. WO050310; 2013
   Google Scholar
• Taisho Pharmaceutical Co, Ltd. Ethinyl-pyrazole derivative. WO015024; 2012
   Google Scholar
• Taisho Pharmaceutical Co, Ltd. Heteroaryl-pyrazole derivative. WO020820; 2012
   Google Scholar
• Taisho Pharmaceutical Co, Ltd. Pyrazole derivative. WO099200; 2012
   Google Scholar
• Taisho Pharmaceutical Co, Ltd. N-Substituted pyrazole derivative. WO111796; 2013
   Google Scholar
• Domain Therapeutics. Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors. WO174822; 2013
   Google Scholar
• Schann S, Manteau B, Deshons L, et al. Molecular switch strategy delivers distinct group II mGluR allosteric modulator families. General Poster Session – EVE Session. 246th ACS National Meeting; 8 – 12 Sept 2013; Indianapolis, IN
   Google Scholar
• Wenthur CJ, Morrison RD, Daniels JS, et al. Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu2/mGlu3 NAMs. Bioorg Med Chem Lett 2014;24(12):2693-8
   PubMed Web of Science ®Google Scholar
• Eisai R&D management & Co. Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative. WO133022; 2014
   Google Scholar
• Merck Sharp &Dohme Corp. Quinolinecarboxamide and quinolinecarbonitrile derivatives as mGlur2-negative allosteric modulators, compositions, and their use. WO066736; 2013
   Google Scholar
• Rorick-Kehn LM, Perkins EJ, Knitowski KM, et al. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 2006;316(2):905-13
   PubMed Web of Science ®Google Scholar
• Danysz W. LY-544344. Eli Lilly. IDrugs 2005;8(9):755-62
   PubMedGoogle Scholar
• Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011;31(3):349-55
   PubMed Web of Science ®Google Scholar
• Lambeng N, Kalinichev M, Perry B, et al. ADX92639, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 2 (mGluR2) improves recognition memory in rodent models relevant to Alzheimer’s disease [abstract 620.14]. 2012 Society For Neuroscience meeting; 13 – 17th October 2012; New Orleans, LA
   Google Scholar
• Steckler T, Aerts N, VerDonck L, Talpos J. Effects of mGluR2 blockade on operant delayed non-matching to position in rats. Current Neuropharmacol 2014;12(Suppl 1):58; abstract 151
   Google Scholar
• Zhang Z, Brownell AL. Imaging of metabotropic glutamate receptors (mGluRs) Chapter 2. In: Bright P, editor. Neuroimaging - clinical applications. InTech; Rijeka,Croatia;978-953-51-0200-7
   Google Scholar
• Andrés JI, Alcázar J, Cid JM, et al. Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem 2012;55(20):8685-99
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. Radiolabelled mGluR2 PET ligands. WO062752; 2012
   Google Scholar
• ARTDeCo study: a study of RO4995819 in patients with major depressive disorder and inadequate response to ongoing antidepressant treatment. Available from: www.clinicaltrials.gov/show/NCT01457677 [Last accessed 28 July 2014]
   Google Scholar
• A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Available from: www.clinicaltrialsregister.eu/ctr-search/trial/2011-002160-24/DE [Last accessed 28 July 2014]
   Google Scholar